India In-Vitro Diagnostics Market Size and Share

India In-Vitro Diagnostics Market by Type (Reagents, Instruments, and Software & Services), by Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), by Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Others) – Opportunity Analysis and Industry Forecast, 2024–2030

Download PDF

Speak to Our Analyst

Market In-Vitro Diagnostics Market Overview

The India In-Vitro Diagnostics Market size was valued at USD 2.64 billion in 2023, and is predicted to reach USD 4.40 billion by 2030, at a CAGR of 7.17% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions.

Immunodiagnostic tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.
These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, in-vitro experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Strong Growth of India's Medical Device Industry Fuels Market Expansion

The robust growth of the medical device industry in the country serves as a key driver for the India in-vitro diagnostics market expansion. According to Department of Pharmaceuticals, the medical device sector is emerging as a sunrise industry in the Indian economy, demonstrating substantial growth momentum. In fiscal year 2021-22, India's medical device exports reached USD 2.9 billion, marking a notable increase of 15.47% compared to the previous fiscal year.

The rise of India's medical device sector has led to greater investment in healthcare infrastructure and technology and enables the way for the adoption of advanced diagnostic solutions such as in-vitro diagnostics, supported by growing exports and demand for healthcare products globally.

As India's healthcare landscape evolves, driven by advancements in medical devices, the in-vitro diagnostics market is poised to improve accessibility, affordability, and quality of diagnostic services, driving overall growth and progress in the sector.

Increasing Prevalence of Cancer in India Boosts Market Growth

The prevalence of cancer in the country significantly drives the India in-vitro diagnostics market growth. According to National Institutes of Health, in 2022, India witnessed approximately 14,61,427 new cancer cases, about one in every nine individuals in the country may face cancer during their lifetime.

The surge in cancer rates in India underscores the urgent need for advanced diagnostic solutions, driving significant demand for immunodiagnostics technologies. These technologies play a crucial role in enabling accurate cancer diagnosis, monitoring disease progression, and customizing personalized treatment strategies.

High Research, Development, and Regulatory Approval Costs Hinder the Market Growth

High costs associated with research, development, and regulatory approval are significant factors restraining the India in-vitro diagnostics market growth. Operating within this sector necessitates significant financial investment for companies to navigate the complex landscape of research and development. This investment often encompasses extensive clinical trials, laboratory testing, and product refinement to guarantee accuracy and reliability.

Additionally, obtaining regulatory approvals from agencies such as the FDA requires strict adherence to stringent standards, further compounding the financial burden. This financial constraint can discourage potential adopters from market expansion.

Introduction of Point-of-Care Testing Solutions in IVD Creates Market Opportunity

Point-of-care testing (POCT) is poised to significantly drive the India IVD market demand in the forthcoming years. POCT serves as a valuable complement to laboratory testing, especially in situations where immediate results are crucial, such as emergency departments, ambulances, and remote healthcare settings.

With POCT technologies offering rapid tests for infectious diseases, cardiac markers, glucose monitoring, pregnancy testing, and more, healthcare providers can quickly assess patients' conditions and make timely treatment decisions.

By integrating POCT with traditional IVD, healthcare providers can enhance their diagnostic capabilities, delivering more efficient and patient-centered care. This integration streamlines workflows, allowing for faster diagnosis and treatment initiation, ultimately leading to improved patient outcomes.

Competitive Landscape

The promising players operating in the India in-vitro diagnostics industry include Abbott Laboratories, Roche Holding AG, Mindray Bio-Medical Electronics Co.,Ltd., Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., Bio-Rad Laboratories, Inc., Proton Biologicals India, Nihon Kohden Corporation , DiaSorin, Agilent Technologies, Inc, and others.

India In-Vitro Diagnostics Market Key Segments

By Type

Reagents
Instruments
Software & Services

By Technique

Immunodiagnostics
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Rapid Tests
- Chemiluminescence Immunoassay (CLIA)
- Enzyme-linked Immunosorbent spot (ELISpot)
- Radioimmunoassay (RIA)
- Western Blot
Hematology
Molecular Diagnostics
- PCR
  - Monoplex PCR
  - Multiplex PCR
- INAAT
- Hybridization
- DNA diagnostics
- Microarray
- Other Molecular Diagnostics
Tissue Diagnostics
Clinical Chemistry
- Basic Metabolic Panel
- Liver Panel
- Renal Profile
- Lipid Profile
- Thyroid Function Panel
- Electrolyte Panel
- Speciality Chemicals
Other IVD Techniques

By Application

Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Others Indications

By End User

Stand Alone Laboratory
Hospitals
Academics and Medical Schools
Point of Care Testing
Other End Users

Key Players

Abbott Laboratories
Roche Holding AG
Mindray Bio-Medical Electronics Co.,Ltd.
Thermo Fisher Scientific Inc
Danaher Corporation
Becton, Dickinson and Company
Siemens Healthineers AG
bioMérieux SA
Sysmex Corporation
QIAGEN N.V.
Bio-Rad Laboratories, Inc.
Proton Biologicals India
Nihon Kohden Corporation
DiaSorin
Agilent Technologies, Inc

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Market Size Value in 2023	USD 2.64 billion
Revenue Forecast in 2030	USD 4.40 billion
Value Growth Rate	CAGR of 7.17% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Billion (USD)
Growth Factors	Strong Growth of India's Medical Device Industry Fuels Market Expansion. Increasing Prevalence of Cancer in India Boosts the Market Growth.
Companies Profiled	15
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

1. 1.1 REPORT DESCRIPTION
2. 1.2 RESEARCH METHODOLOGY
3. 1. 1.2.1 SECONDARY RESEARCH
  2. 1.2.2 DATA ANALYSIS FRAMEWORK
  3. 1.2.3 MARKET SIZE ESTIMATION
  4. 1.2.4 FORECASTING
  5. 1.2.5 PRIMARY RESEARCH AND DATA VALIDATION

1. 2.1. MARKET SNAPSHOT, 2024 - 2030, BILLION USD

1. 3.1 BARGAINING POWER OF SUPPLIERS
2. 3.2 BARGAINING POWER OF BUYERS
3. 3.3 DEGREE OF COMPETITION
4. 3.4 THREAT OF SUBSTITUTE
5. 3.5 THREAT OF NEW ENTRANTS

1. 4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2024

1. 5.1 GROWTH DRIVERS
2. 1. 5.1.1 STRONG GROWTH OF INDIA'S MEDICAL DEVICE INDUSTRY FUELS MARKET EXPANSION
  2. 5.1.2 INCREASING PREVALENCE OF CANCER IN INDIA BOOSTS MARKET GROWTH
3. 5.2 CHALLENGES
4. 1. 5.2.1 HIGH RESEARCH, DEVELOPMENT, AND REGULATORY APPROVAL COSTS HINDER THE MARKET GROWTH
5. 5.3 OPPORTUNITIES
6. 1. 5.3.1 INTRODUCTION OF POINT-OF-CARE TESTING SOLUTIONS IN IVD CREATES MARKET OPPORTUNITY 6 INDIA IN VITRO DIAGONOSTIC MARKET BY PRODUCT TYPE
7. 6.1 OVERVIEW
8. 6.2 REAGENTS MARKET
9. 6.3 INSTRUMENTS MARKET
10. 6.4 SOFTWARE AND SERVICES MARKET

1. 7.1 OVERVIEW
2. 7.2 IMMUNODIAGNOSTICS MARKET
3. 1. 7.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
  2. 7.2.2 RAPID TESTS
  3. 7.2.3 CHEMILUMINESCENCE IMMUNOASSAY (CLIA)
  4. 7.2.4 ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT)
  5. 7.2.5 RADIOIMMUNOASSAY (RIA)
  6. 7.2.6 WESTERN BLOT
4. 7.3 HEMATOLOGY MARKET
5. 7.4 MOLECULAR DIAGNOSTICS MARKET
6. 1. 7.4.1 PCR
  2. 1. 7.4.1.1 MONOPLEX PCR
    2. 7.4.1.2 MULTIPLEX PCR
  3. 7.4.2 INAAT
  4. 7.4.3 HYBRIDIZATION
  5. 7.4.4 DNA DIAGNOSTICS
  6. 7.4.5 MICROARRAY
  7. 7.4.6 OTHER MOLECULAR DIAGNOSTICS
7. 7.5 TISSUE DISGNOSTICS MARKET
8. 7.6 CLINICAL CHEMISTRY MARKET
9. 1. 7.6.1 BASIC METABOLIC PANEL
  2. 7.6.2 LIVER PANEL
  3. 7.6.3 RENAL PROFILE
  4. 7.6.4 LIPID PROFILE
  5. 7.6.5 THYROID FUNCTION PANEL
  6. 7.6.6 ELECTROLYTE PANEL
  7. 7.6.7 SPECIALITY CHEMICALS
10. 7.7 OTHER IVD TECHNIQUES MARKET

1. 8.1 OVERVIEW
2. 8.2 INFECTIOUS DISEASES MARKET
3. 8.3 CANCER MARKET
4. 8.4 CARDIAC DISEASES MARKET
5. 8.5 IMMUNE SYSTEM DISORDERS MARKET
6. 8.6 NEPHROLOGICAL DISEASES MARKET
7. 8.7 GASTROINTESTINAL DISEASES MARKET
8. 8.8 OTHER INDICATIONS MARKET

1. 9.1 OVERVIEW
2. 9.2 STAND ALONE LABORATORY MARKET
3. 9.3 HOSPITALS MARKET
4. 9.4 ACADEMICS AND MEDICAL SCHOOLS MARKET
5. 9.5 POINT OF CARE TESTING MARKET
6. 9.6 OTHER END-USERS MARKET

1. 10.1 ABBOTT LABORATORIES
2. 1. 10.1.1 COMPANY OVERVIEW
  2. 10.1.2 COMPANY SNAPSHOT
  3. 10.1.3 OPERATING BUSINESS SEGMENTS
  4. 10.1.4 PRODUCT PORTFOLIO
  5. 10.1.5 BUSINESS PERFORMANCE
  6. 10.1.6 BUSINESS SEGMENTS
  7. 10.1.7 GEOGRAPHIC SEGMENTS
  8. 10.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.1.9 PRIMARY MARKET COMPETITORS
3. 10.2 ROCHE HOLDING AG
4. 1. 10.2.1 COMPANY OVERVIEW
  2. 10.2.2 COMPANY SNAPSHOT
  3. 10.2.3 OPERATING BUSINESS SEGMENTS
  4. 10.2.4 PRODUCT PORTFOLIO
  5. 10.2.5 BUSINESS PERFORMANCE
  6. 10.2.6 BUSINESS SEGMENTS
  7. 10.2.7 GEOGRAPHIC SEGMENTS
  8. 10.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.2.9 PRIMARY MARKET COMPETITORS
5. 10.3 MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.
6. 1. 10.3.1 COMPANY OVERVIEW
  2. 10.3.2 COMPANY SNAPSHOT
  3. 10.3.3 OPERATING BUSINESS SEGMENTS
  4. 10.3.4 PRODUCT PORTFOLIO
  5. 10.3.5 BUSINESS PERFORMANCE
  6. 10.3.6 BUSINESS SEGMENTS
  7. 10.3.7 GEOGRAPHIC SEGMENTS
  8. 10.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.3.9 PRIMARY MARKET COMPETITORS
7. 10.4 THERMO FISHER SCIENTIFIC INC
8. 1. 10.4.1 COMPANY OVERVIEW
  2. 10.4.2 COMPANY SNAPSHOT
  3. 10.4.3 OPERATING BUSINESS SEGMENTS
  4. 10.4.4 PRODUCT PORTFOLIO
  5. 10.4.5 BUSINESS PERFORMANCE
  6. 10.4.6 BUSINESS SEGMENTS
  7. 10.4.7 GEOGRAPHIC SEGMENTS
  8. 10.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.4.9 PRIMARY MARKET COMPETITORS
9. 10.5 DANAHER CORPORATION
10. 1. 10.5.1 COMPANY OVERVIEW
  2. 10.5.2 COMPANY SNAPSHOT
  3. 10.5.3 OPERATING BUSINESS SEGMENTS
  4. 10.5.4 PRODUCT PORTFOLIO
  5. 10.5.5 BUSINESS PERFORMANCE
  6. 10.5.6 BUSINESS SEGMENTS
  7. 10.5.7 GEOGRAPHIC SEGMENTS
  8. 10.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.5.9 PRIMARY MARKET COMPETITORS
11. 10.6 BECTON, DICKINSON AND COMPANY
12. 1. 10.6.1 COMPANY OVERVIEW
  2. 10.6.2 COMPANY SNAPSHOT
  3. 10.6.3 OPERATING BUSINESS SEGMENTS
  4. 10.6.4 PRODUCT PORTFOLIO
  5. 10.6.5 BUSINESS PERFORMANCE
  6. 10.6.6 BUSINESS SEGMENTS
  7. 10.6.7 GEOGRAPHIC SEGMENTS
  8. 10.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.6.9 PRIMARY MARKET COMPETITORS
13. 10.7 SIEMENS HEALTHINEERS AG
14. 1. 10.7.1 COMPANY OVERVIEW
  2. 10.7.2 COMPANY SNAPSHOT
  3. 10.7.3 OPERATING BUSINESS SEGMENTS
  4. 10.7.4 PRODUCT PORTFOLIO
  5. 10.7.5 BUSINESS PERFORMANCE
  6. 10.7.6 BUSINESS SEGMENTS
  7. 10.7.7 GEOGRAPHIC SEGMENTS
  8. 10.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.7.9 PRIMARY MARKET COMPETITORS
15. 10.8 BIOMÉRIEUX SA
16. 1. 10.8.1 COMPANY OVERVIEW
  2. 10.8.2 COMPANY SNAPSHOT
  3. 10.8.3 OPERATING BUSINESS SEGMENTS
  4. 10.8.4 PRODUCT PORTFOLIO
  5. 10.8.5 BUSINESS PERFORMANCE
  6. 10.8.6 BUSINESS SEGMENTS
  7. 10.8.7 GEOGRAPHIC SEGMENTS
  8. 10.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.8.9 PRIMARY MARKET COMPETITORS
17. 10.9 SYSMEX CORPORATION
18. 1. 10.9.1 COMPANY OVERVIEW
  2. 10.9.2 COMPANY SNAPSHOT
  3. 10.9.3 OPERATING BUSINESS SEGMENTS
  4. 10.9.4 PRODUCT PORTFOLIO
  5. 10.9.5 BUSINESS PERFORMANCE
  6. 10.9.6 BUSINESS SEGMENTS
  7. 10.9.7 GEOGRAPHIC SEGMENTS
  8. 10.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.9.9 PRIMARY MARKET COMPETITORS
19. 10.10 QIAGEN N.V.
20. 1. 10.10.1 COMPANY OVERVIEW
  2. 10.10.2 COMPANY SNAPSHOT
  3. 10.10.3 OPERATING BUSINESS SEGMENTS
  4. 10.10.4 PRODUCT PORTFOLIO
  5. 10.10.5 BUSINESS PERFORMANCE
  6. 10.10.6 BUSINESS SEGMENTS
  7. 10.10.7 GEOGRAPHIC SEGMENTS
  8. 10.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.10.9 PRIMARY MARKET COMPETITORS
21. 10.11 BIO-RAD LABORATORIES, INC.
22. 1. 10.11.1 COMPANY OVERVIEW
  2. 10.11.2 COMPANY SNAPSHOT
  3. 10.11.3 OPERATING BUSINESS SEGMENTS
  4. 10.11.4 PRODUCT PORTFOLIO
  5. 10.11.5 BUSINESS PERFORMANCE
  6. 10.11.6 BUSINESS SEGMENTS
  7. 10.11.7 GEOGRAPHIC SEGMENTS
  8. 10.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.11.9 PRIMARY MARKET COMPETITORS
23. 10.12 PROTON BIOLOGICALS INDIA
24. 1. 10.12.1 COMPANY OVERVIEW
  2. 10.12.2 COMPANY SNAPSHOT
  3. 10.12.3 OPERATING BUSINESS SEGMENTS
  4. 10.12.4 PRODUCT PORTFOLIO
  5. 10.12.5 BUSINESS PERFORMANCE
  6. 10.12.6 BUSINESS SEGMENTS
  7. 10.12.7 GEOGRAPHIC SEGMENTS
  8. 10.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.12.9 PRIMARY MARKET COMPETITORS
25. 10.13 NIHON KOHDEN CORPORATION
26. 1. 10.13.1 COMPANY OVERVIEW
  2. 10.13.2 COMPANY SNAPSHOT
  3. 10.13.3 OPERATING BUSINESS SEGMENTS
  4. 10.13.4 PRODUCT PORTFOLIO
  5. 10.13.5 BUSINESS PERFORMANCE
  6. 10.13.6 BUSINESS SEGMENTS
  7. 10.13.7 GEOGRAPHIC SEGMENTS
  8. 10.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.13.9 PRIMARY MARKET COMPETITORS
27. 10.14 DIASORIN
28. 1. 10.14.1 COMPANY OVERVIEW
  2. 10.14.2 COMPANY SNAPSHOT
  3. 10.14.3 OPERATING BUSINESS SEGMENTS
  4. 10.14.4 PRODUCT PORTFOLIO
  5. 10.14.5 BUSINESS PERFORMANCE
  6. 10.14.6 BUSINESS SEGMENTS
  7. 10.14.7 GEOGRAPHIC SEGMENTS
  8. 10.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.14.9 PRIMARY MARKET COMPETITORS
29. 10.15 AGILENT TECHNOLOGIES, INC
30. 1. 10.15.1 COMPANY OVERVIEW
  2. 10.15.2 COMPANY SNAPSHOT
  3. 10.15.3 OPERATING BUSINESS SEGMENTS
  4. 10.15.4 PRODUCT PORTFOLIO
  5. 10.15.5 BUSINESS PERFORMANCE
  6. 10.15.6 BUSINESS SEGMENTS
  7. 10.15.7 GEOGRAPHIC SEGMENTS
  8. 10.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.15.9 PRIMARY MARKET COMPETITORS

TABLE 1. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
TABLE 2. REAGENTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 3. INSTRUMENTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 4. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 5. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
TABLE 6. IMMUNODIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 7. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 8. RAPID TESTS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 9. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 10. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 11. RADIOIMMUNOASSAY (RIA), MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 12. WESTERN BLOT, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 13. HEMATOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 14. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 15. PCR, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 16. INAAT, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 17. HYBRIDIZATION, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 18. DNA DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 19. MICROARRAY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 20. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 21. TISSUE DISGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 22. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 23. BASIC METABOLIC PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 24. LIVER PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 25. RENAL PROFILE, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 26. LIPID PROFILE, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 27. THYROID FUNCTION PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 28. ELECTROLYTE PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 29. SPECIALITY CHEMICALS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 30. OTHER IVD TECHNIQUES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 31. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
TABLE 32. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 33. CANCER, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 34. CARDIAC DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 35. IMMUNE SYSTEM DISORDERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 36. NEPHROLOGICAL DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 37. GASTROINTESTINAL DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 38. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 39. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
TABLE 40. STAND ALONE LABORATORY, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 41. HOSPITALS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 42. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 43. POINT OF CARE TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 44. OTHER END-USERS, MARKET VALUE, 2024-2030, (BILLION USD)
TABLE 45. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 46. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 47. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 48. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 49. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 50. ABBOTT LABORATORIES: KEY STRATERGY
TABLE 51. ROCHE HOLDING AG: COMPANY SNAPSHOT
TABLE 52. ROCHE HOLDING AG: OPERATING BUSINESS SEGMENTS
TABLE 53. ROCHE HOLDING AG: PRODUCT PORTFOLIO
TABLE 54. ROCHE HOLDING AG: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 55. ROCHE HOLDING AG: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 56. ROCHE HOLDING AG: KEY STRATERGY
TABLE 57. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: COMPANY SNAPSHOT
TABLE 58. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: OPERATING BUSINESS SEGMENTS
TABLE 59. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: PRODUCT PORTFOLIO
TABLE 60. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 61. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 62. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: KEY STRATERGY
TABLE 63. THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT
TABLE 64. THERMO FISHER SCIENTIFIC INC: OPERATING BUSINESS SEGMENTS
TABLE 65. THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
TABLE 66. THERMO FISHER SCIENTIFIC INC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 67. THERMO FISHER SCIENTIFIC INC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 68. THERMO FISHER SCIENTIFIC INC: KEY STRATERGY
TABLE 69. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 70. DANAHER CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 71. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 72. DANAHER CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 73. DANAHER CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 74. DANAHER CORPORATION: KEY STRATERGY
TABLE 75. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 76. BECTON, DICKINSON AND COMPANY: OPERATING BUSINESS SEGMENTS
TABLE 77. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 78. BECTON, DICKINSON AND COMPANY: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 79. BECTON, DICKINSON AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 80. BECTON, DICKINSON AND COMPANY: KEY STRATERGY
TABLE 81. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 82. SIEMENS HEALTHINEERS AG: OPERATING BUSINESS SEGMENTS
TABLE 83. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 84. SIEMENS HEALTHINEERS AG: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 85. SIEMENS HEALTHINEERS AG: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 86. SIEMENS HEALTHINEERS AG: KEY STRATERGY
TABLE 87. BIOMéRIEUX SA: COMPANY SNAPSHOT
TABLE 88. BIOMéRIEUX SA: OPERATING BUSINESS SEGMENTS
TABLE 89. BIOMéRIEUX SA: PRODUCT PORTFOLIO
TABLE 90. BIOMéRIEUX SA: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 91. BIOMéRIEUX SA: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 92. BIOMéRIEUX SA: KEY STRATERGY
TABLE 93. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 94. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 95. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 96. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 97. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 98. SYSMEX CORPORATION: KEY STRATERGY
TABLE 99. QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 100. QIAGEN N.V.: OPERATING BUSINESS SEGMENTS
TABLE 101. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 102. QIAGEN N.V.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 103. QIAGEN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 104. QIAGEN N.V.: KEY STRATERGY
TABLE 105. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 106. BIO-RAD LABORATORIES, INC.: OPERATING BUSINESS SEGMENTS
TABLE 107. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 108. BIO-RAD LABORATORIES, INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 109. BIO-RAD LABORATORIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 110. BIO-RAD LABORATORIES, INC.: KEY STRATERGY
TABLE 111. PROTON BIOLOGICALS INDIA: COMPANY SNAPSHOT
TABLE 112. PROTON BIOLOGICALS INDIA: OPERATING BUSINESS SEGMENTS
TABLE 113. PROTON BIOLOGICALS INDIA: PRODUCT PORTFOLIO
TABLE 114. PROTON BIOLOGICALS INDIA: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 115. PROTON BIOLOGICALS INDIA: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 116. PROTON BIOLOGICALS INDIA: KEY STRATERGY
TABLE 117. NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT
TABLE 118. NIHON KOHDEN CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 119. NIHON KOHDEN CORPORATION: PRODUCT PORTFOLIO
TABLE 120. NIHON KOHDEN CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 121. NIHON KOHDEN CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 122. NIHON KOHDEN CORPORATION: KEY STRATERGY
TABLE 123. DIASORIN: COMPANY SNAPSHOT
TABLE 124. DIASORIN: OPERATING BUSINESS SEGMENTS
TABLE 125. DIASORIN: PRODUCT PORTFOLIO
TABLE 126. DIASORIN: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 127. DIASORIN: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 128. DIASORIN: KEY STRATERGY
TABLE 129. AGILENT TECHNOLOGIES, INC: COMPANY SNAPSHOT
TABLE 130. AGILENT TECHNOLOGIES, INC: OPERATING BUSINESS SEGMENTS
TABLE 131. AGILENT TECHNOLOGIES, INC: PRODUCT PORTFOLIO
TABLE 132. AGILENT TECHNOLOGIES, INC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 133. AGILENT TECHNOLOGIES, INC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 134. AGILENT TECHNOLOGIES, INC: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (BILLION USD)
FIGURE 7. REAGENTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 8. INSTRUMENTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 9. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 10. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY TECHNIQUE, 2024-2030, (BILLION USD)
FIGURE 11. IMMUNODIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 12. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 13. RAPID TESTS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 14. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 15. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 16. RADIOIMMUNOASSAY (RIA), MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 17. WESTERN BLOT, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 18. HEMATOLOGY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 19. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 20. PCR, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 21. INAAT, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 22. HYBRIDIZATION, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 23. DNA DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 24. MICROARRAY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 25. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 26. TISSUE DISGNOSTICS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 27. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 28. BASIC METABOLIC PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 29. LIVER PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 30. RENAL PROFILE, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 31. LIPID PROFILE, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 32. THYROID FUNCTION PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 33. ELECTROLYTE PANEL, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 34. SPECIALITY CHEMICALS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 35. OTHER IVD TECHNIQUES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 36. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY APPLICATION, 2024-2030, (BILLION USD)
FIGURE 37. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 38. CANCER, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 39. CARDIAC DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 40. IMMUNE SYSTEM DISORDERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 41. NEPHROLOGICAL DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 42. GASTROINTESTINAL DISEASES, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 43. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 44. INDIA IN VITRO DIAGONOSTIC MARKET VALUE, BY END-USER, 2024-2030, (BILLION USD)
FIGURE 45. STAND ALONE LABORATORY, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 46. HOSPITALS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 47. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 48. POINT OF CARE TESTING, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 49. OTHER END-USERS, MARKET VALUE, 2024-2030, (BILLION USD)
FIGURE 50. ABBOTT LABORATORIES: NET SALES, (2022-2024)
FIGURE 51. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 52. ROCHE HOLDING AG: NET SALES, (2022-2024)
FIGURE 53. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS
FIGURE 54. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: NET SALES, (2022-2024)
FIGURE 55. MINDRAY BIO-MEDICAL ELECTRONICS CO.,LTD.: PRIMARY MARKET COMPETITORS
FIGURE 56. THERMO FISHER SCIENTIFIC INC: NET SALES, (2022-2024)
FIGURE 57. THERMO FISHER SCIENTIFIC INC: PRIMARY MARKET COMPETITORS
FIGURE 58. DANAHER CORPORATION: NET SALES, (2022-2024)
FIGURE 59. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 60. BECTON, DICKINSON AND COMPANY: NET SALES, (2022-2024)
FIGURE 61. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS
FIGURE 62. SIEMENS HEALTHINEERS AG: NET SALES, (2022-2024)
FIGURE 63. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS
FIGURE 64. BIOMéRIEUX SA: NET SALES, (2022-2024)
FIGURE 65. BIOMéRIEUX SA: PRIMARY MARKET COMPETITORS
FIGURE 66. SYSMEX CORPORATION: NET SALES, (2022-2024)
FIGURE 67. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 68. QIAGEN N.V.: NET SALES, (2022-2024)
FIGURE 69. QIAGEN N.V.: PRIMARY MARKET COMPETITORS
FIGURE 70. BIO-RAD LABORATORIES, INC.: NET SALES, (2022-2024)
FIGURE 71. BIO-RAD LABORATORIES, INC.: PRIMARY MARKET COMPETITORS
FIGURE 72. PROTON BIOLOGICALS INDIA: NET SALES, (2022-2024)
FIGURE 73. PROTON BIOLOGICALS INDIA: PRIMARY MARKET COMPETITORS
FIGURE 74. NIHON KOHDEN CORPORATION: NET SALES, (2022-2024)
FIGURE 75. NIHON KOHDEN CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 76. DIASORIN: NET SALES, (2022-2024)
FIGURE 77. DIASORIN: PRIMARY MARKET COMPETITORS
FIGURE 78. AGILENT TECHNOLOGIES, INC: NET SALES, (2022-2024)
FIGURE 79. AGILENT TECHNOLOGIES, INC: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

We conduct SWOT analysis to understand market trends, identify potential threats, capitalize on opportunities, and assess our strengths and weaknesses.

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Frequently Asked Questions

The India in-vitro diagnostics market revenue is estimated to reach up to USD 4.40 billion by 2030.

The key players in the India in-vitro diagnostics industry include Abbott Laboratories, Roche Holding AG, Mindray Bio-Medical Electronics Co.,Ltd., Thermo Fisher Scientific Inc, Danaher Corporation, Becton, Dickinson and Company, Siemens Healthineers AG, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., Bio-Rad Laboratories, Inc., Proton Biologicals India, Nihon Kohden Corporation , DiaSorin, Agilent Technologies, Inc, and others.

The India in-vitro diagnostics market size was estimated at USD 2.64 billion in 2023.

High costs associated with research, development, and regulatory approval are significant factors restraining the India IVD market growth.

Introduction of Point-of-Care Testing (POCT) solutions creates opportunities for the India in-vitro diagnostics market in the coming future.

Download Free Sample

Phone Number *

Please enter Country Code and Phone No

Yes, I have read the Privacy Policy

Multi User

$2,575

Single User

$1,575

Enterprise

$3,875

Datapack

$1,975

Download Sample

Inquire Before Buying